Sutura, Inc.
OTC Bulletin Board : SUTU

Sutura, Inc.

November 01, 2005 14:45 ET

Sutura to Spin Off New Vascular Suturing Device Company

FOUNTAIN VALLEY, CALIFORNIA--(CCNMatthews - Nov. 1, 2005) - Sutura, Inc. ("Sutura") (OTCBB:SUTU), a California-based medical device company, announced today that it intends to spin-off one of its proprietary suturing device products into a new company. The new company will be dedicated to the development and commercialization of its separate line of HeartStitch® suturing devices.

The still-to-be formed company, whose name will be announced later this month, will be a spin-off of Sutura, Inc. The details of the spin-off also will be announced later this month, but it is intended that the new Company be self-financed and that current shareholders of Sutura will receive shares in the spin-off company.

The innovative HeartStitch suturing device is designed for use in the closing procedure during transcatheter management of common atrial septal defects (ASDs) and patent foramen ovale (PFO). Atrial septal defect is an abnormality of the upper chambers of the heart where the wall between the right and left atria does not close completely. These Septal defects, which are present at birth, are sometimes called a "hole" in the heart. A patent foramen ovale (PFO) is a defect in the septum (wall) between the two upper chambers of the heart. Specifically, the defect is an incomplete closure of the atrial septum that results in the creation of a flap or a valve-like opening in the atrial septal wall. A PFO is frequent in everyone before birth but seals shut in about 80% of people.

"The establishment of the new Company will enable Sutura to further focus on the sale and development of its SuperStitch vascular suturing device, particularly as we prepare to introduce the new 12F SuperStitch design in the first quarter of next year," said Anthony Nobles, CEO/President of Sutura. "By launching one of our products via a Company spun-off of Sutura, we hope to provide increased value to our shareholders, and give the investment community a 'pure play' with respect to our medical device businesses."

About Sutura, Inc.

Sutura®, Inc. ( is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.
Within the United States the 8F & 6F SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch 8F & 6F is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", "appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including consummation of the intended spin-off of the AFD and PFO lines of business and the structure of such transaciton, the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed sales and marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Contact Information